Journal Article10.1016/J.JCLINEPI.2013.02.003
GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength.
Jeffrey C Andrews,Holger J. Schünemann,Andrew D Oxman,Kevin Pottie,Joerg J Meerpohl,Pablo Alonso Coello,David Rind,Victor M. Montori,Juan P. Brito,Susan L Norris,Mahmoud Elbarbary,Piet N. Post,Mona Nasser,Vijay K Shukla,Roman Jaeschke,Jan Brozek,Ben Djulbegovic,Gordon H. Guyatt +17 more
1.1K
TL;DR: This article addresses GRADE's approach to determining the direction and strength of a recommendation, which describes the balance of desirable and undesirable outcomes of interest among alternative management strategies depending on four domains, namely estimates of effect for desirable and desirable outcomes ofinterest, confidence in the estimates ofEffect, estimates of values and preferences, and resource use.
read more
About: This article is published in Journal of Clinical Epidemiology. The article was published on 01 Jul 2013.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Embedding patients' values and preferences in guideline development for allergic diseases: The case study of Allergic Rhinitis and its Impact on Asthma 2024
Rafael José Vieira,Bernardo Sousa‐Pinto,Antonio Bognanni,Juan José Yepes‐Nuñez,Yuan Zhang,Justyna Lityńska,Ewelina Sadowska,E Borowiack,Ulysse Rodts,Alkis Togias,Torsten Zuberbier,Jean Bousquet,Mario Sánchez-Borges +12 more
TL;DR: Embedding patients' values and preferences in guideline development for allergic diseases considers the relative importance patients place on outcomes and uses this information to balance desirable and undesirable effects.
ERS and ATS diagnostic guidelines for primary ciliary dyskinesia: similarities and differences in approach to diagnosis.
TL;DR: Primary ciliary dyskinesia (PCD) is a genetically and clinically heterogeneous disease, usually inherited in an autosomal recessive pattern, and some women are sub-fertile because of immotile cilia in the Fallopian tubes.
Values and Preferences Related to Cancer Risk among Red and Processed Meat Eaters: A Pilot Cross-Sectional Study with Semi-Structured Interviews
Victoria Howatt,Anna Prokop-Dorner,Claudia Valli,Joanna Zajac,Malgorzata M Bala,Pablo Alonso-Coello,Gordon H. Guyatt,Bradley C. Johnston +7 more
TL;DR: In this article, a pilot cross-sectional study was conducted to explore people's values and preferences towards eating red and processed meats in the face of cancer risk and found that about half of the participants were willing to potentially reduce their meat consumption, with one third definitely willing to reduce their consumption.
Marcos GRADE de la evidencia a la decisión (EtD): un enfoque sistemático y transparente para tomar decisiones sanitarias bien informadas. 1: Introducción
Pablo Alonso-Coello,Holger J. Schünemann,Jenny Moberg,Romina Brignardello-Petersen,Romina Brignardello-Petersen,Elie A. Akl,Elie A. Akl,Marina Davoli,Shaun Treweek,Reem A. Mustafa,Reem A. Mustafa,Gabriel Rada,Sarah Rosenbaum,Angela Morelli,Gordon H. Guyatt,Andrew D Oxman +15 more
TL;DR: Los marcos EtD informan a los usuarios sobre los juicios que se han hecho y la evidencia que los apoya dotando de transparencia the base for las decisiones de los que tienen que tomarlas.
References
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
Jacques E. Rossouw,Garnet L. Anderson,Ross L. Prentice,Andrea Z. LaCroix,Charles Kooperberg,Marcia L. Stefanick,Rebecca D. Jackson,Shirley A.A. Beresford,Barbara V. Howard,Karen C. Johnson,Jane Morley Kotchen,Judith K. Ockene +11 more
TL;DR: Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables
Gordon H. Guyatt,Andrew D Oxman,Elie A. Akl,Regina Kunz,Gunn Elisabeth Vist,Jan Brozek,Susan L Norris,Yngve Falck-Ytter,Paul Glasziou,Hans deBeer,Roman Jaeschke,David Rind,Joerg J Meerpohl,Philipp Dahm,Holger J. Schünemann +14 more
TL;DR: The GRADE process begins with asking an explicit question, including specification of all important outcomes, and provides explicit criteria for rating the quality of evidence that include study design, risk of bias, imprecision, inconsistency, indirectness, and magnitude of effect.
8.6K
GRADE guidelines: 3. Rating the quality of evidence
Howard Balshem,Mark Helfand,Mark Helfand,Holger J. Schünemann,Andrew D Oxman,Regina Kunz,Jan Brozek,Gunn Elisabeth Vist,Yngve Falck-Ytter,Joerg J Meerpohl,Susan L Norris,Gordon H. Guyatt +11 more
TL;DR: The approach of GRADE to rating quality of evidence specifies four categories-high, moderate, low, and very low-that are applied to a body of evidence, not to individual studies.
7.1K
Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Clive Kearon,Elie A. Akl,Anthony J. Comerota,Paolo Prandoni,Henri Bounameaux,Samuel Z. Goldhaber,Michael E. Nelson,Philip S. Wells,Michael K. Gould,Francesco Dentali,Mark Crowther,Susan R. Kahn +11 more
TL;DR: Strong recommendations apply to most patients, whereas weak recommendations are sensitive to differences among patients, including their preferences.
6.3K
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
Stephen B. Hulley,Deborah Grady,Trudy L. Bush,Curt D Furberg,David M. Herrington,Betty Riggs,Eric Vittinghoff +6 more
TL;DR: Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease and the treatment did increase the rate of thromboembolic events and gallbladder disease.
6.2K